In recent years, angioplasty with drug-eluting stents (DES) has emerged as an alternative to myocardial revascularization surgery in patients with left main coronary artery disease. Both European and American guidelines offer a Class IIa recommendation for left main coronary artery (LMCA) angioplasty in selected patients. The EXCEL (Evaluation of Xience Versus Coronary Artery Bypass Surgery for<a href="https://solaci.org/en/2018/01/11/quality-of-life-between-surgery-and-angioplasty-for-the-treatment-of-left-main-disease/" title="Read more" >...</a>
Coronary Angioplasty Is a Valid Alternative for Left Main Coronary Artery Disease
Courtesy of Dr. Carlos Fava. Severe left main coronary artery (LMCA) lesions have a bad prognosis in coronary disease. In that scenario, current guidelines recommend surgery as the treatment of choice. However, due to the current development of second-generation drug-eluting stents (DES) and greater operator expertise, left main coronary artery angioplasty appears as a valid alternative<a href="https://solaci.org/en/2018/01/05/coronary-angioplasty-is-a-valid-alternative-for-left-main-coronary-artery-disease/" title="Read more" >...</a>
Aspirin During Noncardiac Surgery: Only in Patients with Prior Angioplasty
A new analysis from the POISE-2 study suggests that aspirin should not be withheld prior to noncardiac surgery in patients with a history of coronary angioplasty, even if their coronary procedure occurred several years earlier. Patients with a history of coronary angioplasty who need cardiac surgery are more likely to benefit from continued aspirin therapy,<a href="https://solaci.org/en/2018/01/02/aspirin-during-noncardiac-surgery-only-in-patients-with-prior-angioplasty/" title="Read more" >...</a>
7 articles on angioplasty that can draw your attention
1) Balloon Angioplasty: A Reasonable Plan B for Chronic Thromboembolic Hypertension Thromboembolic pulmonary hypertension is caused by pulmonary artery stenosis caused by organized thrombi. The only treatment potentially healing for this disease is surgical thrombectomy. However, patients with lesions in very peripheral branches or high surgical risk patients with comorbidities might benefit from a plan B,<a href="https://solaci.org/en/2017/11/27/7-articles-on-angioplasty-that-can-draw-your-attention/" title="Read more" >...</a>
Balloon Angioplasty: A Reasonable Plan B for Chronic Thromboembolic Hypertension
Thromboembolic pulmonary hypertension is caused by pulmonary artery stenosis caused by organized thrombi. The only treatment potentially healing for this disease is surgical thrombectomy. However, patients with lesions in very peripheral branches or high surgical risk patients with comorbidities might benefit from a plan B, such as balloon pulmonary angioplasty. The percentage of patients with chronic<a href="https://solaci.org/en/2017/11/27/balloon-angioplasty-a-reasonable-plan-b-for-chronic-thromboembolic-hypertension/" title="Read more" >...</a>
Ischemic and Bleeding Risk After Primary Angioplasty
Patients with ST-segment elevation myocardial infarction who undergo primary angioplasty are at high risk for both ischemic and bleeding events, which affect significantly both morbidity and mortality. An optimal selection of antithrombotic therapies in terms of strength and duration must take into account the timing for the procedure, since the risk for these complications may<a href="https://solaci.org/en/2017/11/22/ischemic-and-bleeding-risk-after-primary-angioplasty/" title="Read more" >...</a>
Angioplasty Complexity May Define the Duration of Dual Antiplatelet Therapy
The DAPT study concluded that continued thienopyridine plus aspirin beyond a year after coronary angioplasty is associated with a decrease in the rate of stent thrombosis and major cardiovascular events. In contrast, there is a significant increase in moderate to severe bleeding when compared with continued aspirin alone. Based on the outcomes of this and<a href="https://solaci.org/en/2017/11/21/angioplasty-complexity-may-define-the-duration-of-dual-antiplatelet-therapy/" title="Read more" >...</a>
TCT 2017 | FAME 2 at 3 Years: Better Results with Angioplasty and at a Cost Similar to Medical Treatment
Courtesy of SBHCI. Angioplasty in patients with chronic stable angina and functionally significant lesions improves clinical outcomes and quality of life over the long term, as compared with optimal medical therapy alone. Furthermore, the invasive approach becomes more cost-effective as the years go by. Previously, FAME 2 had shown that angioplasty was initially more expensive, but<a href="https://solaci.org/en/2017/11/06/tct-2017-fame-2-at-3-years-better-results-with-angioplasty-and-at-a-cost-similar-to-medical-treatment/" title="Read more" >...</a>
TCT 2017 | ORBITA: The Placebo Effect of Angioplasty
Courtesy of the SBHCI. Chronic stable angina and severe coronary lesion patients who undergo angioplasty in a single vessel show no better outcomes than individuals who undergo a placebo sham procedure when it comes to exercise capacity and symptoms, according to this study presented at TCT and published simultaneously in the Lancet. The curious results<a href="https://solaci.org/en/2017/11/06/tct-2017-orbita-the-placebo-effect-of-angioplasty/" title="Read more" >...</a>
Fentanyl in Angioplasty: What Is the Price of More Comfort During the Procedure?
Fentanyl is a potent opiate commonly administered in the cath lab. Recently, questions on its safety have been raised by research demonstrating that intravenous morphine significantly delays the absorption of oral P2Y12 platelet inhibitors. The mechanism might be slowed gastric emptying. The Platelet Aggregation with tiCagrelor Inhibition and FentanYl (PACIFY) trial enrolled 212 patients undergoing indicated<a href="https://solaci.org/en/2017/10/31/fentanyl-in-angioplasty-what-is-the-price-of-more-comfort-during-the-procedure/" title="Read more" >...</a>